Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 14th World Congress on Infection Prevention and Control Valencia, Spain.

Day 1 :

OMICS International Infection Prevention 2018 International Conference Keynote Speaker Francesca J Torriani photo

Francesca J Torriani, is a Professor of Medicine in the Division of Infectious Diseases (ID) at the University of California, San Diego (UCSD). She received her M.D. in 1985 from the University Medical School in Lausanne, Switzerland and joined UCSD’s faculty in 1995.In addition to her clinical work, she serves as the Medical Director of the UCSD Health IPCE. Dr. Torriani helped create the legislation on HAI and Antimicrobial Stewardship reporting in California. She continues on the Metrics Group for CA HAI Reporting, an independent group of experts on best standards and methods for HAI prevention. She is well published (>75).


Prevention of Healthcare Associated Infections has been the focus of Infection Prevention and Quality Initiatives for more than two decades, and multidrug resistant organisms are responsible for many of these infections, further complicating their treatment.
In addition to strengthening antimicrobial stewardship practices, and improving adherence to standard precautions (including hand hygiene), contact precautions for patients colonized or infected with multidrug resistant organisms have been recommended and widely adopted to prevent horizontal transmission in the acute care healthcare setting. However, the data supporting these recommendations derives predominantly from epidemic rather than endemic settings, where the burden of transmission as well as the transmission rate is by definition high. Guidelines underscore the importance of a basic multiprong approach that includes education around epidemiologically important organisms, hand hygiene, contact precautions, environmental cleaning and antimicrobial stewardship. Additional measures recommended in the outbreak setting, such as active screening for MDR GNR, MRSA and VRE, alerts for previous positives with pre-emptive CP, and cohorting of patients and staff, etc have also been proposed on occasion. The presenter will discuss the strengths and weaknesses of these strategies when used alone or in conjunction, and will argue that the focus on the primacy of contact precautions in acute care settings is misplaced for most MDR organisms. Alternative focus and practices will be proposed.

Keynote Forum

Ionel Victor Pătraşcu

Activeimmunity srl, Romania

Keynote: Biological products pi-2a II-oral and topical treatment of pediatric psoriasis

Time : 10:40 AM- 11:20 AM

OMICS International Infection Prevention 2018 International Conference Keynote Speaker Ionel Victor Pătraşcu photo

Ionel Victor Pătraşcu MVD, PhD president of Activeimmunity, born on February 7, 1937. Graduated in Veterinary Medicine in Bucharest in 1963. Researcher in the field of virusology at Pasteur Institute in Bucharest. Made different specializations in the field of avian and human oncogenic viruses at Houghton Poultry Research Station, Huntington, England, at Friedrich-Loeffler- Institut, Celle, Institute of Animal Pathology in Rotherdam, Netherlands, Cornell University Ithaca NY and Athens University, Athens, GA. USA.In 1971 discovered to extract Fc 126 cell associated as cell free in SPGA and allowed to freeze-dry vaccine anti Marek disease lymphoma. He made the first research Center in the world at Voluntari, Romania, called Avian Tumor Viruses Lab, where specialists from England, U.S., France, Bulgaria, the German Democratic Republic, Hungary, the USSR, and China came to do studies in the period of the Iron Curtain and communist politics from Moscow. In 1989 discovered the largest outbreak in the world of HIV infection and AIDS in children in Romania.Studied antibiotic resistance of microorganisms and made first immunogen I-PC2 used biological preclinical and clinical human studies and the second generation of immunogen I-spga that was managed to prepare IMUNOVIP able to react specifically with superbugs infection by oral treatment of antibiotic-resitant urinary tract infections in women. During 1965-2017 he dealt with the training of specialists who are now valuable researchers, professors and academics.



Introduction: Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1–3% of the white population. Although two incidence peaks have been suggested (in adolescence and adulthood), the onset may occur at any age, including childhood (1). Guidelines for pediatric psoriasis treatment are lacking due to side effects of therapies approved for treatment in adult patients. In this study we show that the treatment of psoriasis-affected children with Avian Immunologically Active Proteins (PI-2A) obtained using our patented technology under Romanian brands IMUNOINSTANT and IMUNOVIP (2-4) was followed by impressive resolution of clinical symptoms without reported side effects. PI-2A are a novel class of biological agents that target specific mediators of inflammation as well as antimicrobial resistant (AMR) microorganisms. Multiple studies have confirmed their efficacy in the treatment of psoriasis in adults (3). “Standard” PI-2A contain antibodies against a panel of 22 microbial antigens; they are formulated as sterile solution, sterile spray, granules, ointments, healing oily liquid, healing granules, healing tablets with easily adsorbable collagen VII, sterile yolk suspension. “Personalized” PI-2A are prepared similarly from pathological materials taken from
psoriasis plaques of individual patients.
Study design: 15 children aged 3 to 12 years presenting severe psoriasis vulgaris were treated with “standard” PI-2A formulated as
oral preparations (sterile solution, granules) and topic preparations (healing oily liquid, sterile yolk suspension) during a 3 months session. Subjects were excluded if presenting history of allergic reaction to egg-derived products. Evaluated parameters were: severity of skin lesions, presence and evolution of fingernail pitting.
Results: The evolution of skin and fingernail lesions was favourable for the entire group of studied subjects (Figure 1 shows two representative cases). There were no reports of intolerance or adverse reactions to the oral and topic use of PI-2A.
Conclusion: PI-2A are an important too in the treatment of pediatric psoriasis.

Keynote Forum

Sharad Kumar Yadav

Veterinary University, India

Keynote: Recent advances in phage display technology
OMICS International Infection Prevention 2018 International Conference Keynote Speaker Sharad Kumar Yadav photo

Sharad Kumar Yadav has 28 years of teaching and research experience and has served to various senior positions of the University including Registrar of the DUVASU University. He is currently Professor, Head of Department of Veterinary Microbiology, and Director at Cow Research Institute at DUVASU, Mathura India. He has published number of papers in reputed International & National journals and has a vast experience in the arena of BHV-I virus.



Emergence of prokaryotic and eukaryotic expression system for the use of antibody production in the beginning years of 1980s was a surprise entry for the new era of ‘IMMUNOTECHNOLOGY’ [a branch of biotechnology that employs sets to bio-technique for the production of immunobiologicals]. Entry of phage display system during the years of 1990s for the antibody fragment expression has been created a bigger achievement and turned into a milestone, which concludes the method of phage display technology for the production of small fragments of antibodies that must possess the quality and the characteristic of binding to the antigens specifically which are popularly and most commonly known as Nanobodies. Phage display technology is a simpler, less time consuming and more efficient approach than the conventional methodology of the antibody production, which contains a number of component for the production of small fragment specific antibodies that includes the target or the antigen in anticipation to the ligand or binder or the antibody which are meant to be produced, next to this it concludes a Phage Display Library, A Phage system, Appropriate Selection or screening process, Appropriate Expression and purification system. The most common bacteriophages used are M13, and FD filamentous phage, though T4, T7 and λ Phage have also been used in some cases.